ImmunityBio, Inc. vs Johnson & Johnson
IBRX vs JNJ — side-by-side comparison from reported financials. IBRX leads 2, JNJ leads 5 of 7 comparable metrics.
ImmunityBio, Inc.
IBRX · Healthcare
$10.57+6.66%Strained
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | IBRX | JNJ |
|---|---|---|
| Price | $10.57 | $261.79 |
| Market cap | $11.2B | $631B |
| Revenue (TTM) | $166M | $97.9B |
| Revenue growth | +678.6% | +5.6% |
| Net margin | -598.6% | 21.5% |
| Free cash flow | -$288M | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | +333.2% | +37.0% |
| P/E | — | 29.9 |
| P/E vs own history (cheap-side %) | — | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -193% | 26% |
| Altman Z-score | -6.14 | — |
| CV checks passed | 4 of 9 | 10 of 9 |
| Employees | 691 | 140,800 |
Full résumé-style profiles: IBRX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.